NCI 9448: Phase I study of trametinib in combination with chemoradiation for KRAS-mutant non-small cell lung cancer.

Steven Hsesheng Lin,Isabel Mok,David Leos,Manolo Pasia,Peter F. Thall,Heather Lin,M.X. Welliver,Miguel A. Villalona-Calero,James C. Yao,Funda Meric-Bernstam,Ritsuko Komaki,Helen X. Chen,George R. Blumenschein

NCI 9448: Phase I study of trametinib in combination with chemoradiation for KRAS-mutant non-small cell lung cancer.

2015

Steven Hsesheng Lin
Isabel Mok
David Leos
Manolo Pasia
Peter F. Thall
Heather Lin
M.X. Welliver
Miguel A. Villalona-Calero
James C. Yao
Funda Meric-Bernstam
Ritsuko Komaki
Helen X. Chen
George R. Blumenschein

TPS7585 Background: Concurrent chemoradiotherapy is the standard management approach for unresectable, non-metastatic locally advanced non-small cell lung cancer (NSCLC). However, progress has been...

Keywords:

Cell
KRAS
Oncology
Lung cancer
Trametinib
Mutant
Medicine
Internal medicine
locally advanced
phase i study
non small cell
Approaches of management

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations